Table 1.
Correlation between NCAPG2 and clinic-pathological examined by TCGA-LGG database.
| Characteristic | Low expression of NCAPG2 | High expression of NCAPG2 | p |
|---|---|---|---|
| n | 264 | 264 | |
| WHO grade, n (%) | < 0.001 | ||
| G2 | 144 (30.8%) | 80 (17.1%) | |
| G3 | 88 (18.8%) | 155 (33.2%) | |
| IDH status, n (%) | < 0.001 | ||
| WT | 29 (5.5%) | 68 (13%) | |
| Mut | 233 (44.4%) | 195 (37.1%) | |
| 1p/19q codeletion, n (%) | < 0.001 | ||
| codel | 109 (20.6%) | 62 (11.7%) | |
| non-codel | 155 (29.4%) | 202 (38.3%) | |
| Primary therapy outcome, n (%) | < 0.001 | ||
| PD | 34 (7.4%) | 76 (16.6%) | |
| SD | 69 (15.1%) | 77 (16.8%) | |
| PR | 40 (8.7%) | 24 (5.2%) | |
| CR | 84 (18.3%) | 54 (11.8%) | |
| Race, n (%) | 0.560 | ||
| Asian | 3 (0.6%) | 5 (1%) | |
| Black or African American | 9 (1.7%) | 13 (2.5%) | |
| White | 245 (47.4%) | 242 (46.8%) | |
| Age, n (%) | 0.068 | ||
| <=40 | 143 (27.1%) | 121 (22.9%) | |
| >40 | 121 (22.9%) | 143 (27.1%) | |
| Histological type, n (%) | 0.084 | ||
| Astrocytoma | 86 (16.3%) | 109 (20.6%) | |
| Oligoastrocytoma | 68 (12.9%) | 66 (12.5%) | |
| Oligodendroglioma | 110 (20.8%) | 89 (16.9%) | |
| OS event, n (%) | < 0.001 | ||
| Alive | 222 (42%) | 170 (32.2%) | |
| Dead | 42 (8%) | 94 (17.8%) | |
| DSS event, n (%) | < 0.001 | ||
| Alive | 224 (43.1%) | 173 (33.3%) | |
| Dead | 37 (7.1%) | 86 (16.5%) | |
| PFI event, n (%) | < 0.001 | ||
| Alive | 186 (35.2%) | 132 (25%) | |
| Dead | 78 (14.8%) | 132 (25%) | |
| Age, meidan (IQR) | 39 (31, 50.25) | 42.5 (33, 54.25) | 0.017 |
G2, grade II; G3, grade III; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; OS event, Overall survival event; DSS event, disease specific survival; and PFI event, progression –free survival.